TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31200349

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise of moderate to vigorous intensity 3 times per week until the end of treatment, then twice per week for 10 weeks, followed by once per week for 10 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise of moderate to vigorous intensity
Number of subjects: 73
Study: 28460809

Group type: EXPERIMENTAL
Intervention: Ultrasound guided Inter‐Scalene Brachial Plexus Block (ISBPB) with lidocaine and epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Procedural Sedation and Analgesia (PSA) with propofol and fentanyl
Number of subjects: 60
Study: 25531162

Group type: EXPERIMENTAL
Intervention: GS-4997 (ASK1 inhibitor), once daily, oral administration
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard of care therapy
Number of subjects: 300
Study: 24101040

Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide (arm 2) for 6 to 12 cycles
Number of subjects: 833

Group type: COMPARATOR
Intervention: Standard temozolomide (arm 1) for 6 to 12 cycles
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: MGMT methylation status
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide (arm 2)
Number of subjects: 833
Study: 20924597

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 19655403

Group type: EXPERIMENTAL
Intervention: 2 Hz EA
Number of subjects: 20

Group type: COMPARATOR
Intervention: SA
Number of subjects: 20

Group type: COMPARATOR
Intervention: MA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 Hz TENS
Number of subjects: 20
Study: 16428531

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (Group 1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.15% (Group 2)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.175% (Group 3)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% (Group 4)
Number of subjects: 4
Study: 15683501

Group type: COMPARATOR
Intervention: Metoprolol 200 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day
Number of subjects: 100
Study: 12064924

Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25‐dihydroxyvitamin D3; 0.25‐3.0 microg/day) alone for the first 6 months with ceredase/cerezyme at 60 IU/kg every 2 weeks during months 7‐12
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Calcitriol together with ceredase/cerezyme at 60 IU/kg every 2 weeks during months 1‐6
Number of subjects: 29

Group type: COMPARATOR
Intervention: Enzyme only at 60 IU/kg body wt every 2 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All groups (calcitriol and enzyme therapy)
Number of subjects: 29
Study: 10458121

Group type: EXPERIMENTAL
Intervention: 0.2 percent topical glyceryl trinitrate ointment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 7531326

Group type: EXPERIMENTAL
Intervention: Plasma testosterone (T)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Plasma estradiol (E2)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Plasma estrone (E1)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 320
Study: 2195567

Group type: EXPERIMENTAL
Intervention: Preoperative prophylaxis with benzylpenicillin and dicloxacillin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 328139

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant trials incorporating radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation alone or in combination with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy followed by immunotherapy
Number of subjects: 0
Study: 31590189

Group type: EXPERIMENTAL
Intervention: Accumulated 2 h light‐intensity treadmill desk walking
Number of subjects: 21

Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 21
Study: 28924366

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine in combination with fentanyl-based IV-PCA (dIV-PCA group)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Conventional thoracic E-PCA (E-PCA group)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Fentanyl-based IV-PCA only (IV-PCA group)
Number of subjects: 171
Study: 25264671

Group type: EXPERIMENTAL
Intervention: Vented mouthguard (VentMG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional mouthguard (TradMG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no mouthguard)
Number of subjects: 15
Study: 23589703

Group type: EXPERIMENTAL
Intervention: Health-promoting behaviors
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Factors affecting resilience in high-risk group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Factors affecting resilience in early CKD group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Factors affecting resilience in pre-ESRD group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 150
Study: 21863672

Group type: EXPERIMENTAL
Intervention: AS03(A)‐adjuvanted H5N1 influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐adjuvanted H5N1 vaccine formulations
Number of subjects: 0
Study: 18671296

Group type: EXPERIMENTAL
Intervention: Midurethral tape (MUT) insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Preoperative URP measurement
Number of subjects: 100
Study: 17301074

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 7707

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 7707
Study: 15129754

Group type: EXPERIMENTAL
Intervention: Audiovisual training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory training
Number of subjects: 0
Study: 11565978

Group type: EXPERIMENTAL
Intervention: Accident terminology questionnaire
Number of subjects: 183

Group type: COMPARATOR
Intervention: Injury terminology questionnaire
Number of subjects: 183
Study: 9692166

Group type: EXPERIMENTAL
Intervention: albendazole (alb) 600 mg + ivermectin (iver) 400 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: albendazole (alb) 600 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: albendazole (alb) 600 mg + diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: diethylcarbamazine (DEC) 6 mg/kg + ivermectin (iver) 400 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: albendazole (alb) + diethylcarbamazine (DEC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: albendazole (alb) + ivermectin (iver)
Number of subjects: 50

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 50
Study: 7599511

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg daily for 60 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3075602

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid ingestion during exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo during exercise
Number of subjects: 8
Study: 31721978

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor copayment reduction intervention (vouchers waiving copayments for 1 year)
Number of subjects: 8373
Study: 31068500

Group type: EXPERIMENTAL
Intervention: NPVS-R instrument
Number of subjects: 329
Study: 27037007

Group type: EXPERIMENTAL
Intervention: Phase I interpretation of cases with preceding diagnosis of ductal carcinoma in situ (DCIS) or invasive cancer
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Phase II interpretation of cases with preceding diagnosis of ductal carcinoma in situ (DCIS) or invasive cancer
Number of subjects: 152
Study: 25551562

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Motivational Interviewing + Normative Feedback (MI+NF)
Number of subjects: 48
Study: 23474238

Group type: EXPERIMENTAL
Intervention: What happens next training
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Expert commentary training
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Hybrid commentary training (expert plus self‐generated commentaries)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Full training package (what happens next plus hybrid commentary training)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Full training package
Number of subjects: 233
Study: 21455043

Group type: EXPERIMENTAL
Intervention: Individualized comprehensive self-management intervention
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 173
Study: 17653851

Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine (TX)
Number of subjects: 209

Group type: COMPARATOR
Intervention: doxorubicin/cyclophosphamide (AC)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: both TX and AC
Number of subjects: 209
Study: 17171602

Group type: EXPERIMENTAL
Intervention: Relapse-Prevention Plan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group Psychoeducation
Number of subjects: 0
Study: 15103479

Group type: EXPERIMENTAL
Intervention: Moist environment dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand washing, wound cleansing, and debridement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical negative pressure, maggot therapy, electromagnetic therapy, therapeutic ultrasound, growth factors
Number of subjects: 0
Study: 11035391

Group type: EXPERIMENTAL
Intervention: Melanotan II
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9355585

Group type: EXPERIMENTAL
Intervention: Paper tape measurements
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cloth tape measurements
Number of subjects: 49
Study: 1288660

Group type: EXPERIMENTAL
Intervention: Low-dose levodopa, bromocriptine, or a combination of both drugs
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (spouses, friends of PD patients, community volunteers)
Number of subjects: 107
Study: 3936760

Group type: EXPERIMENTAL
Intervention: PGI2 (8 ng/kg/min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PGI2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (glycine buffer)
Number of subjects: 40
Study: 31561360

Group type: EXPERIMENTAL
Intervention: MILD[+] patients
Number of subjects: 1198

Group type: COMPARATOR
Intervention: MILD[-] patients
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Patients with amyloid[-]
Number of subjects: 1198
Study: 29373734

Group type: EXPERIMENTAL
Intervention: Testosterone treatment for 36 months
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo treatment for 36 months
Number of subjects: 308
Study: 27832623

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at six points (ST34, SP10, SP9, ST36, ST35, EX‐LE4)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at four points (ST34, SP10, ST35, EX‐LE5)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at two points (ST35, EX‐LE4)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 132
Study: 25080051

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 ppm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham inhaled nitric oxide administration
Number of subjects: 50
Study: 22924950

Group type: EXPERIMENTAL
Intervention: PUVA + bexarotene
Number of subjects: 93

Group type: COMPARATOR
Intervention: PUVA alone
Number of subjects: 93
Study: 20673983

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - Budesonide
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 1041
Study: 18343541

Group type: EXPERIMENTAL
Intervention: 23‐valent pneumococcal polysaccharide vaccine
Number of subjects: 1298
Study: 15641062

Group type: EXPERIMENTAL
Intervention: Combination treatment (methotrexate + etanercept)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 682

Group type: COMPARATOR
Intervention: Monotherapy (methotrexate or etanercept)
Number of subjects: 682
Study: 12130441

Group type: EXPERIMENTAL
Intervention: MR cholangiopancreatography
Number of subjects: 26

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 26
Study: 11465011

Group type: EXPERIMENTAL
Intervention: Individual and group psychotherapy, cognitive-behavioral therapy, 12-step programmes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serotonin (5-hydroxytryptamine; 5-HT) re-uptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Debt consolidation and credit counselling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-help books
Number of subjects: 0
Study: 9459044

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg enteric-coated tablet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Omeprazole 20 mg capsule
Number of subjects: 40
Study: 7963448

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 708
Study: 3306891

Group type: EXPERIMENTAL
Intervention: 1 g ASA and 1 g sucralfate four times daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1 g ASA four times daily and placebo tablets
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: No drugs administered
Number of subjects: 16
Study: 31629621

Group type: EXPERIMENTAL
Intervention: LCS Complete DUOFIX (porous coating plus HA and pegs)
Number of subjects: 197

Group type: COMPARATOR
Intervention: LCS Complete POROCOAT (porous coating only)
Number of subjects: 197
Study: 29880291

Group type: EXPERIMENTAL
Intervention: Olaparib and abiraterone
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo and abiraterone
Number of subjects: 142
Study: 28118620

Group type: EXPERIMENTAL
Intervention: Higher levels of urine albumin-to-creatinine ratio (UACR)
Number of subjects: 2620

Group type: EXPERIMENTAL
Intervention: Lower estimated glomerular filtration rate (eGFR)
Number of subjects: 2620

Group type: COMPARATOR
Intervention: Control for covariates
Number of subjects: 2620
Study: 26162632

Group type: EXPERIMENTAL
Intervention: Rituximab 1000mg twice at 2 weeks interval
Number of subjects: 175
Study: 24001083

Group type: EXPERIMENTAL
Intervention: fosphenytoin (fPHT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: lacosamide
Number of subjects: 200
Study: 21700754

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 73

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 73
Study: 18086726

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16868064

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (strict blood glucose control to normoglycemia with insulin)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group (no intensive insulin therapy)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration (replacement dose)
Number of subjects: 451
Study: 12757066

Group type: EXPERIMENTAL
Intervention: Standard needle aspiration (Group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nylon probing (Group B)
Number of subjects: 16
Study: 11097068

Group type: EXPERIMENTAL
Intervention: Preparing for Parenthood intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Routine antenatal care only
Number of subjects: 190
Study: 9086340

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Oral micronized 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Oral tibolone
Number of subjects: 109
Study: 8461075

Group type: EXPERIMENTAL
Intervention: Na-naproxen
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 29558923

Group type: EXPERIMENTAL
Intervention: Incentive intervention (1-in-10 chance of winning a £50 shopping voucher for returning a signed consent form)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Incentive intervention
Number of subjects: 242
Study: 27805982

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) followed by a 12-week exercise intervention
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 12
Study: 26604653

Group type: EXPERIMENTAL
Intervention: BS capsules containing glucoraphanin (GR) for 2 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BS extract in animal model
Number of subjects: 52
Study: 23164309

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus daily enemas for 2 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 71
Study: 21823381

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block with bupivacaine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration of the skin and subcutaneous tissue
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (saline TAP block)
Number of subjects: 55
Study: 18655817

Group type: EXPERIMENTAL
Intervention: Daily ingestion of a strong-gelling sodium alginate formulation for 7 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 17152782

Group type: EXPERIMENTAL
Intervention: Bileaflet valve
Number of subjects: 37

Group type: COMPARATOR
Intervention: Monoleaflet valve
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Prosthesis diameter
Number of subjects: 37
Study: 12689798

Group type: EXPERIMENTAL
Intervention: 8-month integrated dietary/breast health intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 256
Study: 10972603

Group type: EXPERIMENTAL
Intervention: Hemofiltration performed with a polysulfone hemofilter during rewarming on cardiopulmonary bypass
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional procedure (Control)
Number of subjects: 26
Study: 8786777

Group type: EXPERIMENTAL
Intervention: Gabexate (1 g by intravenous infusion starting 30 to 90 minutes before endoscopy and continuing for 12 hours afterward)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Gabexate
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo (mannitol and sodium chloride administered in the same fashion)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 1440818

Group type: EXPERIMENTAL
Intervention: Moderate and heavy S. haematobium infection
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Presence of splenomegaly
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: History of treated infection
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Presence of periportal fibrosis
Number of subjects: 422
Study: 3994929

Group type: EXPERIMENTAL
Intervention: 5% dextrose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% dextrose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hartmann's solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 31640315

Group type: EXPERIMENTAL
Intervention: Breathing-exercise programme (BE)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fartlek-training (FT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Interval-training (IT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Constant-training (CT)
Number of subjects: 69
Study: 29690714

Group type: EXPERIMENTAL
Intervention: 70 kVp + ADMIRE (group 1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: linear blending + ADMIRE (group 2)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 100 kVp + SAFIRE (group 3)
Number of subjects: 74
Study: 25881568

Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft ACL reconstruction
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Quadruple-stranded hamstring tendon (HT) autograft ACL reconstruction
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) hamstring autograft ACL reconstruction
Number of subjects: 330
Study: 24970272

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (130/0.4) + 500 ml of Ringer's lactate (HES group)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Ringer's lactate (1000 ml) (RL group)
Number of subjects: 167
Study: 22641931

Group type: EXPERIMENTAL
Intervention: Support person present
Number of subjects: 129

Group type: COMPARATOR
Intervention: No support person present (Control)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Caregivers present with a patient
Number of subjects: 129
Study: 20186402

Group type: EXPERIMENTAL
Intervention: Combined kinetic and visual guidance
Number of subjects: 39

Group type: COMPARATOR
Intervention: Kinetic guidance
Number of subjects: 39

Group type: COMPARATOR
Intervention: Visual guidance
Number of subjects: 39
Study: 17105795

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (60 to 64 Gy of external beam radiotherapy delivered to the prostatic fossa)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Usual care plus observation
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 425
Study: 15531687

Group type: EXPERIMENTAL
Intervention: Total calcium intake (>1767 mg/d)
Number of subjects: 3696

Group type: EXPERIMENTAL
Intervention: Calcium supplement use (>1200 mg/d)
Number of subjects: 3696

Group type: EXPERIMENTAL
Intervention: Calcium intake (total and supplemental)
Number of subjects: 3696
Study: 11374604

Group type: COMPARATOR
Intervention: 0 microg/kg intrathecal morphine (saline injection)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 microg/kg intrathecal morphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 microg/kg intrathecal morphine
Number of subjects: 30